Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of RPH-104 (Goflikicept) in Adult Subjects With Schnitzler Syndrome
NCT04213274Phase 2Withdrawn
- Sponsor
- R-Pharm
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of goflikicept in Schnitzler syndrome, sponsored by R-Pharm. Planned start May 2023; status: withdrawn.
02
Drugs
goflikicept
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on NCT04213274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213274.